



PTO/SB/08B(10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submit for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

### Complete if Known

Application Number	09/961,407
Filing Date	September 25, 2001
First Named Inventor	Christopher J. Torrance
Group Art Unit	1614
Examiner Name	N/A
Attorney Docket Number	001107.00140

MAR 14 2002

RECEIVED

TECH CENTER 1600/2900

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KAL	5	JENKINS et al., A novel cell-based assay for the evaluation of anti-ras compounds, Br. J. Cancer, 1993, 69, 856-61	
		KAIN, Green fluorescent protein (GFP): applications in cell-based assays for drug discovery, DDT, 1999, 4, 304-12	
		CORBLEY et al., A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors, Int. J. Cancer, 1996, 66, 753-9	
		STRATOWA et al., A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity, Anti-Cancer Drug Design, 1999, 14, 393-402	

Examiner Signature	<i>Marin G. Gamella</i>	Date Considered	2/17/04
--------------------	-------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.